Susquehanna International Group, LLP Cidara Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.68 - $0.97 $8,762 - $12,499	12,886 New	12,886 $10,000
Q2 2023 Aug 11, 2023	SELL	$1.01 - $1.42 $81,052 - $113,955	-80,250 Reduced 76.79%	24,251 $27,000
Q1 2023 May 16, 2023	BUY	$0.75 - $1.98 $78,375 - $206,911	104,501 New	104,501 $132,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.39 $14,898 - $30,908	-22,236 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.18 - $2.18 $25,135 - $46,436	-21,301 Reduced 48.93%	22,236 $28,000
Q1 2020 May 15, 2020	BUY	$1.74 - $4.26 $58,255 - $142,624	33,480 Added 332.9%	43,537 $108,000
Q4 2019 Feb 14, 2020	SELL	$1.77 - $3.84 $4,798 - $10,410	-2,711 Reduced 21.23%	10,057 $39,000
Q3 2019 Nov 14, 2019	BUY	$1.25 - $2.35 $15,960 - $30,004	12,768 New	12,768 $25,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.